new concerns about using selegiline (Eldepryl) for patients with early Parkinson's disease
There are new concerns about using selegiline (Eldepryl) for patients with early Parkinson's disease.
A surprising British study suggests that adding selegiline to levodopa therapy doesn't slow the progression of Parkinson's...and might increase mortality.
But tell patients not to panic...many experts dispute these findings and say the study was flawed. Most neurologists say that selegiline DOES help certain patients...by improving symptoms and having a levodopa-sparing effect.